Elevar Therapeutics to Share Camrelizumab/Rivoceranib Poster at International Liver Cancer Association Conference on Clinical Outcomes in Younger Age Patients with Unresectable Hepatocellular Carcinoma
BRUSSELS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for cancer patients, today announced that in a post hoc analysis of its Phase 3 CARES-310 study, camrelizumab, an anti-PD-1 antibody, plus rivoceranib, an oral TKI, demonstrated a clinically meaningful progression-free survival (PFS) benefit across all age subgroups when compared to sorafenib in patients with unresectable hepatocellular carcinoma (uHCC).
Read releases like this the second they cross the wire.
1,200+ feeds from 80+ newswires in one live cockpit — saved searches, instant alerts, AI summaries. 7-day free trial, no card required.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live on PPN World.
PPN Source →